Pant Sadip, Neupane Pritam, Ramesh Khatri Chhetri, Barakoti Murari
Sadip Pant, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
World J Cardiol. 2011 Aug 26;3(8):263-6. doi: 10.4330/wjc.v3.i8.263.
Hypertension is of frequent occurrence in the elderly population. Isolated systolic hypertension (ISH) accounts for the majority of cases of hypertension in the elderly. ISH is associated with a 2-4-fold increase in the risk of myocardial infarction, left ventricular hypertrophy, renal dysfunction, stroke, and cardiovascular mortality. There have been many studies to determine the optimal treatment for hypertension in the elderly. Why, when and how to treat hypertension in the elderly was the scope of the majority of these trials. Despite countless efforts many aspects remain obscure. While a number of novel drugs are being developed, the issue of whether all antihypertensive drugs bestow parallel benefits or whether some agents offer a therapeutic advantage beyond blood pressure control remains of crucial importance. Furthermore, the response of the elderly to different antihypertensive agents also differs from that of younger patients and may explain some of the disparities in outcomes of trials conducted in elderly patients with hypertension.
高血压在老年人群中很常见。单纯收缩期高血压(ISH)占老年高血压病例的大多数。ISH与心肌梗死、左心室肥厚、肾功能不全、中风和心血管死亡率风险增加2至4倍相关。已经有许多研究来确定老年高血压的最佳治疗方法。这些试验大多围绕老年高血压患者为何、何时以及如何治疗展开。尽管付出了无数努力,但许多方面仍不明确。虽然正在研发多种新型药物,但所有抗高血压药物是否能带来同等益处,或者某些药物是否能提供超越血压控制的治疗优势,这一问题仍然至关重要。此外,老年人对不同抗高血压药物的反应也与年轻患者不同,这可能解释了在老年高血压患者中进行的试验结果存在差异的部分原因。